What We're Reading: Page 151
Industry reads hand-picked by our editors
Aug 04, 2021
-
The New York Times
F.D.A. Aims to Give Final Approval to Pfizer Vaccine by Early Next Month
-
Bloomberg
SoftBank Build Stake in Roche Worth $5 Billion
-
Endpoints News
Synbio unicorn Zymergen jettisons founding CEO, cuts guidance as customers report lead product doesn't work
-
The Wall Street Journal
Amgen Disputes IRS Claim It Owes $3.6 Billion in Back Taxes
Aug 03, 2021
-
FiercePharma
Bristol Myers pulls an Istodax lymphoma use 10 years after FDA accelerated approval
-
STAT
Even as it breaks biotech’s unwritten rules, Amylyx is raising big money
-
Reuters
Drugmaker Eli Lilly profit hit by weak demand for pandemic drugs
-
Insider
The 24 Biotech Startups That Will Take Off in the Next Year, VCs Say
Aug 02, 2021
-
The Washington Post
FDA vows 'all hands on deck' effort to get Pfizer coronavirus vaccine full approval as quickly as possible
-
MarketWatch
Immunovant Shares Drop After Roivant Opts for Strategic Investment
-
Financial Times
Pfizer and Moderna ramp up EU Covid vaccine prices
-
Reuters
FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings
Jul 30, 2021
-
The Washington Post
‘The war has changed’: Internal CDC document urges new messaging, warns delta infections likely more severe
-
Chemical & Engineering News
Biomanufacturing draws hundreds of millions in investments
-
Bloomberg
Boston's Biotechs Pull Out All the Stops in Hiring Boom 'On Steroids'
-
The Wall Street Journal
Israel to Offer Pfizer Booster Shots to Elderly as Delta Cases Rise
Jul 29, 2021
-
Endpoints News
In CureVac's failure, a possible verdict on the past (and future) of mRNA vaccines
-
Nature
How the coronavirus infects cells — and why Delta is so dangerous
-
MedCity News
AI-driven Deep Genomics gets $180M to turn biology into informational medicines
-
Fierce Biotech
GSK culls phase 2 RSV vaccine in kids, as feladilimab flops again in lung cancer
Jul 28, 2021
Jul 27, 2021
-
The New York Times
At the F.D.A.’s urging, Pfizer-BioNTech and Moderna are expanding their studies of children 5 to 11.
-
The Washington Post
‘A tipping point’: Government officials, health groups move to require coronavirus vaccines for workers
-
Fierce Biotech
Artios raises $153M to fund DNA damage repair clinical trials
Previous
